Compare MD & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MD | NVAX |
|---|---|---|
| Founded | 1979 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 1996 | 1996 |
| Metric | MD | NVAX |
|---|---|---|
| Price | $31.34 | $8.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $30.08 | $14.11 |
| AVG Volume (30 Days) | 688.7K | ★ 6.1M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 263.03 | ★ 309.76 |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $1,913,849,000.00 | $1,123,479,000.00 |
| Revenue This Year | $2.82 | N/A |
| Revenue Next Year | $2.13 | N/A |
| P/E Ratio | $21.94 | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $17.23 | $6.20 |
| 52 Week High | $33.74 | $13.39 |
| Indicator | MD | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 65.09 | 37.52 |
| Support Level | $25.27 | $7.81 |
| Resistance Level | $33.74 | $10.53 |
| Average True Range (ATR) | 1.18 | 0.76 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 54.02 | 5.98 |
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.